2007 Cancer Annual Report - St.Joseph's Hospital

The Future of Cancer Care Is
2007 Cancer Annual Report
with statistical data from 2006
Inside: A Study on Prostate Cancer
Here
W W W . S T J O S E P H S T A M P A . C O M
CANCER INSTITUTE
Advanced medicine in the right hands. SM

Cancer Committee
2006-2007 Members
Anthony Brannan, M.D.
Cancer Committee Chairman
ACoS Liaison
General Surgeon
Manjul Derasari, M.D.
Pain Management
Christopher George, M.D.
Cancer Conference Coordinator
Medical Oncology
Giselle Ghurani, M.D.
GYN Oncology
Gabriel Gonzales-Portillo, M.D.
Neurosurgery
David Hochberg, M.D.
Urology
Brian Jeffrey, M.D.
Pathology
Stephen Kennedy, M.D.
Radiology
Alex Mirakian, M.D.
Radiation Oncology
Joseph Sinkovics, M.D.
Medical Oncology
Cameron Tebbi, M.D.
Pediatric Oncology
Waide Weaver, M.D.
Medical Oncology/Hematology
Cheri Andrews, R.N.
OCN Clinical Inpatient
Holly Anglen
Marketing
Susan Baker, R.N.
Nurse Navigator
Delphine Ballard
Rehabilitation
Christina Bastone
Business Development
Moira Boyd
Social Services
Ronda Buffington, R.N.
OCN Cancer Helpline
Brian Cupari
Marketing
George Francis
Chaplain
Merrianne Furlong
Women’s Health
Kimberly Guy, COO
SJWH (ex-officio)
Kristal Hollingsworth
Lymphedema Program
Whitney Lisica
Lymphedema Program
Lorraine Lutton, COO
SJH (ex-officio)
Dawn MacCartney, R.N.
SJCH
Deanna Macon
Medical Records
Jan Marshburn
Moffitt
Jody Meguiar
Medical Staff Services
Susan Mills, R.N.
Radiation Therapy
Nancy Nethery
ACS Patient Service Representative
Susan Pearce, R.N.
Quality Outcome
Kim Perez, Pharm D.
CI Pharmacy
Janet Pindral
Breast Center
Martha Priede
Medical Staff Services
Mary Pritchard, R.N.
Research/Infusion Center
Julieann Ramsey
CI Administration
Fran Rinchuse, RD
Nutrition
Sharon Shoyer
SJCH Patient Services
Carol Silver
Social Services
John Surprenant
CI Administrative Director
Michele Tison
Lymphedema Program
Laurie Winkles
Marketing
Christina Wirebjer
Lymphedema Program
Victoria Young
CTR Cancer Registry

Table of Contents
Cancer Committee Chairman’s Report ..............................................................................4
What We Know About Prostate Cancer ............................................................................5
Prostate Cancer at St. Joseph’s Hospital (PCE Study) ........................................................6
PCE Study Charts and Graphs ..........................................................................................8
Cancer Registry Data Summary ......................................................................................10
Primary Site Tabulation for Cases in 2006 ......................................................................11
Cancer Registry Report....................................................................................................13
Cancer Liaison Physician Report ....................................................................................13
Cancer-Related Programs and Services ............................................................................14
Cancer Patient Support Services......................................................................................15
2006-2007 Cancer Program Highlights ..........................................................................16
Cancer Research ..............................................................................................................17
Cancer Program Leaders..................................................................................................18
Important Phone Numbers..............................................................................................18
Index of Physicians Associated with Cancer Program......................................................19
Affiliated with…
H. Lee Moffitt Cancer Center & Research Institute
In Partnership with…
American Cancer Society – Formal Hospital Partnership
Axis Palliative Care, LLC – a subsidiary of LifePath Hospice
Florida Dialogue on Cancer – Group working to set cancer priorities in Florida
CureSearch – Unites childhood cancer research organizations to promote research:
Children’s Oncology Group and National Childhood Cancer Foundation
Radiation Therapy Oncology Group

Cancer Committee
Chairman’s Report
The Cancer Committee of St. Joseph’s Hospital is pleased to submit our 2007 Annual Report, which outlines the activities and
accomplishments of our cancer program for the year and provides the statistical information of the cancer patients served at our facility
during 2006.
Statistics indicate that clinical outcomes among patients treated at St. Joseph’s Hospital compare favorably when measured against
benchmark data retrievable from national repositories. This year’s annual report reviews and updates St. Joseph’s Hospital’s experience
with prostate cancer from 2000 to 2006. St. Joseph’s Hospital survival rate from prostate cancer is equal to the state and national
survival rates. There has been a steady rise in the use of robotic prostatectomy over the last four years at St. Joseph’s Hospital reflecting
the increased availability and expertise in the area.
The journey of having a cancer diagnosis and treatment is never a pleasant one. There are physical, psychological and emotional
challenges. We have tried to evaluate and quantify the issue of the patients’ experience at St. Joseph’s Hospital Cancer Institute. Patient
satisfaction surveys for both our inpatient and outpatient cancer care have scored among the highest in the hospital. This is truly a
tribute to the outstanding physicians, nurses and ancillary staff who are dedicated to providing exceptional and compassionate care.
The guiding principles of our cancer program are: the patient comes first, work is a unified effort and excellence is expected in all we
do. Success is a cooperative effort and is dependent upon everyone involved in the care of cancer patients.
This past year has been a very successful year for our Cancer Program. Below are just a few highlights of what has been accomplished.
St. Joseph’s Hospital formally entered into an affiliation relationship with the H. Lee Moffitt Cancer Center & Research Institute,
Florida’s only National Cancer Institute (NCI) designated center. This relationship allows both St. Joseph’s Hospital and the Moffitt
Cancer Center to do what they do best: St. Joseph’s Hospital to provide primary care and Moffitt Cancer Center to conduct research.
St. Joseph’s Hospital led the way in the region by formally entering into a partnership with the American Cancer Society. Through this
partnership, St. Joseph’s Hospital has made a commitment to inform cancer patients of the extended resources available through the
American Cancer Society, as well as other community resources, and to actively promote cancer screening and education. Of special
note, is the selection of St. Joseph’s Hospital to be recognized by the American Cancer Society for its innovative and expanded Reach to
Recovery Breast Program, and for being chosen by the Florida division of the American Cancer Society to be a pilot site for the national
program called Clinician’s Portal. This unique program affords newly diagnosed patients access to timely and customized education,
services and programs.
A dedicated nurse navigator was hired to assist newly diagnosed breast cancer patients at The Breast Center at St. Joseph’s Women’s
Hospital. Various quality initiatives and studies were undertaken to ensure the highest level of care for our patients. Our outreach and
screening programs provided 54 support group meetings with almost 800 patients in attendance; six community educational seminars
on various topics; two region-wide colorectal cancer awareness screening campaigns along with CVS Pharmacies and WFTS – ABC 28 in
which more than 95,000 free screening kits were distributed. The Cancer Institute has held numerous special events including A Special
Cancer Survivors Day Celebration, A Woman’s Journey Through Cancer art exhibition in conjunction with Lilly Pharmaceutical and an
Oncology Nursing Society nurses review course.
The Cancer Program sponsored weekly tumor conferences and held three Grand Rounds presentations on topics important to our
professional staff.
Each year as we reflect on the accomplishments of our cancer professionals, we again want to express appreciation for the enthusiasm
and generosity they bring to their work. With their leadership and support, we are confident in our ability to fulfill our mission to
provide the best cancer services available in our community.
4
Anthony N. Brannan, M.D.
Cancer Committee Chairman
Cancer Liaison Physician

What We Know About Prostate Cancer
Prostate cancer is the most common type of cancer among men and is the
second leading cause of cancer death. It is estimated by the American
Cancer Society that in 2007, there will be 218,890 new cases of prostate
cancer in the United States and 27,050 men, or one in 34, will die from
this disease. The good news is that death rates for prostate cancers are
decreasing and the disease is being detected earlier.
According to the American Cancer Society, the chance of a man having
prostate cancer is one in six. The chance increases as a man gets older;
approximately two of every three prostate cancers are found in men over
the age of 65. Studies suggest that men with close family members
(father, brother, son) who have had prostate cancer are more likely to get
it themselves. Their risk becomes greater if their family member
contracted cancer at an early age. For African-American men, prostate
cancer incidence rates are the highest in the world.
Although we know some of the risk factors linked to prostate cancer, we
do not know what causes most cases. Cancers have different risk factors.
Some risk factors, such as smoking, can be controlled. Others, like a
person’s age or family history, cannot be changed. But having a risk factor,
or even several, does not mean that a person will get prostate cancer.
Doctors can often find prostate cancer early by testing the amount of
prostate-specific antigen (PSA) in the patient’s blood. They can also find it
early by performing a digital rectal exam (DRE). The American Cancer
Society believes that doctors should offer the PSA blood test and a DRE
yearly, beginning at age 50, to men who do not have any major medical
problems. Men at high risk should begin testing at age 45 and include
African-Americans and those with a close relative who had prostate cancer
before age 65.
Patients should discuss options for the best management of their prostate
cancer with their physicians, since more than one treatment option may be
available. The best treatment depends on a number of factors that take into
account the patient’s age, overall health, the stage and grade of cancer, and
the patient’s treatment preferences. Surgery, radiation therapy and hormone
therapy are the most common treatments for prostate cancer.
Chemotherapy may be used in some cases, and for those not on an active
form of treatment, watchful waiting may be an option for some men.
Robotic prostatectomy is the most advanced surgical option for qualifying
prostate cancer patients. The benefits for patients who undergo this
minimally invasive and nerve-sparing surgery include faster recovery times,
less blood loss, less pain and shorter hospital stays.
Men treated for prostate cancer today have a more favorable outlook. In fact,
99 percent of men diagnosed with this disease survive at least five years. In
addition, 90 percent of all prostate cancers are found while they are still
within the prostate or have spread only to nearby areas. The five-year relative
survival rate for these men is nearly 100 percent; clearly revealing the
importance of early detection. Older men who follow a recommended testing
schedule and have regular clinical exams maximize their chances for
detecting and recovering from cancer and other prostate conditions. As with
most types of cancer, the earlier the tumor is discovered, the better the
patient’s chances for survival. Tumors discovered at an early stage often
respond well to treatment. Treatment options vary depending on many
patient factors and should be discussed with a physician.
Prostate Facts at a Glance
• Prostate cancer is the most common type of cancer found in American
men, other than skin cancer.
• Prostate cancer is the second leading cause of cancer death in men.
• The American Cancer Society estimates that there will be about 218,890
new cases of prostate cancer in the United States in 2007. About 27,050
men will die of this disease.
• While one man in six will get prostate cancer during his lifetime, only
one man in 34 will die of this disease.
• African-American men are more likely to have prostate cancer and have a
higher mortality rate than Caucasian or Asian men. The reasons for this
are still unknown.
• Although men of any age can get prostate cancer, it is found most often
in men over 50.
5

Prostate Cancer at St. Joseph’s Hospital
2002-2006 Patient Care Study • PCE Study
6
Dr. George
Dr. Hochberg
Dr. Mastandrea
Dr. Mirakian
The cancer program at St. Joseph’s Hospital last reviewed
prostate cancer in 1999. This study will review and update
the experience with prostate cancer from 2000-2006.
Prostate cancer is the most common non-skin cancer
diagnosed in males in the United States. The annual
incidence is estimated to be approximately 218,000 new
cases in the United States in 2007. Approximately one
man in six will develop prostate cancer in his lifetime,
making the incidence comparable to the incidence of
breast cancer in women. Roughly 27,000 patients are
expected to die of prostate cancer in the year 2007. This
number has decreased approximately 2% per year,
1995-2001. This decline in the death rate may be due to
detection of lower risk disease, increased public awareness
and early detection.
Prostate cancer has an incredible heterogeneity of
behavior. Some men will present with low-grade disease
at an elderly age, with little impact on either the length or
quality of life. Younger men with high-grade disease will
likely have a significantly shortened survival rate. Thus,
the identification and aggressive management of high risk
patients becomes of paramount importance. The biologic
heterogeneity of prostate cancer has led to considerable
controversy in the management of diagnosis and
treatment of prostate cancer. The development of prostatespecific
antigen (PSA) in the late 1980s as a screening and
management tool has led to earlier diagnosis of prostate
cancer. As a result, most patients are now diagnosed with
clinically localized disease. The decision process for
treatment will need to include a number of factors
including Gleason score, age, life expectancy, PSA level,
stage, co-morbidities, and finally patient preference.
Robotic Surgery at St. Joseph’s Hospital
An evolutionary step in prostate cancer treatment has
occurred. With the advent of robotic-assisted laparoscopic
prostatectomy, the surgical treatment of prostate cancer
has changed. Robotic surgery offers a lower risk of
bleeding, incontinence, and improved potency post
procedure, as well as a more rapid recovery for the
patient. This has made robotic surgery the modality of
choice for many patients. St. Joseph’s Hospital has seen
this change occur due to the foresight of this institution in
being one of the first hospitals in Florida to acquire and
use the da Vinci ® Surgical System. Because of this
foresight, more men in our community are choosing
robotic surgery as their treatment of choice for prostate
cancer. St. Joseph’s Hospital has become a Center of
Excellence for robotic surgery. St. Joseph’s Hospital was
the first in the state to purchase and use the da Vinci
system. Because of this, we have acted as a training
center for most of the sites in the state.
The da Vinci robotic surgery system was created to take
laparoscopic surgery to the next level. Using laparoscopic
ports, tubes which permit thin instruments to enter the
body, allowing the performance of more complex
surgeries. The standard laparoscopic instruments do not
allow the surgeon to suture and dissect tissue easily. These
instruments are straight and rigid and seem like
chopsticks. The robotic instruments are thin and straight,
but the ends move like the human hand. This turns the
surgeon’s hands into two seven-millimeter instruments.
This, coupled with the binocular vision, which allows for
depth perception and 10 times magnification of the scope,
gives the surgeon the ability to perform an operation
better than by human hand. We can now do complex
procedures in very small spaces in the body and do them
with superior vision.
Because of these improvements, patients who have robotic
radical prostatectomies need blood transfusions less than
one percent of the time. Compared with open surgery,
this is a great improvement. Also, the incontinence rate
with robotic surgery is much less than with open surgery
and can approach as low as one percent.
Most men with prostate cancer are concerned about
potency after treatment. With robotic surgery and the
more precise dissection of the neurovascular bundle (the
nerves that give a man an erection), most men having this
surgery can be potent afterwards. What men appreciate
most after having robotic surgery is the decreased level of
pain and the rapid return to normal activities.
Rather than spending several days in the hospital and
months afterwards recovering as with open surgery patients,
robotic surgery patients can go home the day after their
surgery and be back to normal activities within two weeks.
St. Joseph’s Hospital is excited to be at the forefront of this
technology, and we are proud to provide this level of care to
our community.

Status of Radiation Therapy at St. Joseph’s Hospital
During the study period 2000-2006, treatment options for prostate cancer
with radiation therapy have undergone numerous developments providing a
drive for change. While radiation therapy has advanced on the technological
front, there has also been the introduction of other competing modalities for
local treatment in the same time period. These include cryosurgical ablation,
laparoscopic prostatectomy and robotic laparoscopic prostatectomy. Data has
also emerged regarding systemic management for intermediate to high risk
patient groups with hormonal therapy and more recently, different
chemotherapeutic combinations.
Previous treatment modalities such as external beam radiotherapy and seed
implantation (a form of low dose rate brachytherapy) have continued as
the main forms of radiation treatment over the past 15 years at St. Joseph’s
Hospital. Newer techniques including the evolution of image guided
radiation therapy (IGRT) have been developed to provide target
identification, enhance treatment delivery and monitor accuracy. All of
these contribute to improvement of the therapeutic rations, allowing gains
in outcome while continuing to minimize toxicity.
Intensity modulated radiation therapy (IMRT), an advanced form of
external beam radiation therapy that has been in use over the study
period at St. Joseph’s Hospital, has facilitated more conformal targeting
and allowed dose escalation to the prostate and surrounding tissues while
minimizing excessive dose to surrounding critical structures such as the
rectum and bladder. This has been of particular importance as studies
have shown that delivering a higher dose to the prostate equates to better
long term control of the cancer as measured by blood levels of prostatespecific
antigen (PSA).
Over the past two to three years, the development and implementation of
IGRT as the latest technological advance has allowed more confidence in
knowing that the delivered dose is actually hitting the target. With this
technology, the position of the prostate is evaluated on a daily basis using
pretreatment implanted marker seeds. Small adjustments are made prior to
each treatment to ensure precise targeting of the gland. St. Joseph’s Hospital
will soon be evaluating this as the next step forward in the technology race.
Low dose rate brachytherapy or prostate seed implantation has continued
as an alternative form of local treatment at St. Joseph’s Hospital, either
alone as monotherapy or in combination with a shorter course of external
beam radiotherapy, usually as IMRT treatment in recent years with
excellent results. Updated data has recently been published on the Seattle
experience, which is the longest worldwide, indicating that after 15 years’
follow-up, their patients are still showing excellent control rates for low
and intermediate risk groups who have previously had this treatment. High
dose rate brachytherapy (HDR), whereby a single radiation seed is used to
deliver the radiation directly into the prostate through hollow catheters
placed within the gland, is also becoming popularized especially due to a
lower rate of side effects.
Overall, St. Joseph’s Hospital is proud to be able to offer the latest in
technology in combination with excellent care and compassion to its
cancer patients. It is clearly the community leader in all aspects of prostate
cancer treatment that it provides evidenced by this latest report of
treatment results over the past five years. St. Joseph’s Hospital will continue
to make available to the community the latest in evolving treatments to
ensure the best possible care of its present and future patients.
The predominant management options for initial therapy of early stage disease
include expectant management, radical prostatectomy and radiotherapy.
Recent studies have verified the importance of using age, life expectancy,
Gleason score and stage in predicting the risk of biochemical failure after local
therapy. Using life table analysis, as well as risk nomograms, one can estimate
the risk of post treatment failure. Cancers can then be categorized as low,
intermediate and high risk cancers. Appropriate treatment selection will
include not only the chance for cure, but also an assessment of co-morbid
illness, side effects of treatment and finally, patient preference.
St. Joseph’s Hospital Prostate Study: 2000-2006
During the period of the study, 1,373 patients were seen and treated at
St. Joseph’s Hospital, with an average of 200 patients per year. This
represents a slight increase over the previous study period (approximately
160/year), but has been fairly stable over the last seven years (Table 1).
Table 1:
Stage of Prostate Cancer – SJH
YEAR STAGE STAGE STAGE STAGE UNK ALL TOTAL
I II III IV OTHERS
Number Number Number Number Number Number Number
2000 1 189 9 7 2 0 208
2001 2 176 4 7 2 1 192
2002 2 175 12 7 1 3 200
2003 1 151 12 7 0 14 185
2004 0 146 19 9 7 1 182
2005 0 169 17 11 0 4 201
2006 0 176 14 7 3 5 205
OTHERS 0 0 0 0 0 0 0
TOTAL 6 1,182 87 55 15 28 1,373
Source: SJH Cancer Registry Database • Retrieved on July 21, 2007
Table 2:
Race of Prostate Cancer Patients – SJH
SJH NON- SPANISH, S. OR CENT. UNK TOTAL
RACE SPANISH HISPANIC AMERICAN
OR LATINO (w/o Brazil)
Number Number Number Number Number
WHITE 952 186 10 3 1,151
BLACK 205 2 2 0 209
FILIPINO 2 0 0 0 2
ASIAN, INDIAN,
PAKISTANI 3 0 0 0 3
VIETNAMESE 1 0 0 0 1
OTHER 0 1 0 1 2
UNKNOWN 4 1 0 0 5
ANY OTHERS 0 0 0 0 0
TOTAL 1,167 190 12 4 1,373
Source: SJH Cancer Registry Database • Retrieved on July 21, 2007
7

Figure 1: Stage of Prostate Cancer Diagnosed in 2004
Florida vs. National
5%
6%
8%
1%
10%
5%
8%
1%
Stage I
Stage II
Stage III
Stage IV
Unknown
Figure 4b:
Surgery – Florida vs. National
None
Local tumor destruction, NOS
Local tumor excision, NOS
Subtotal, segmental, or simple prostatectomy
Radical prostatectomy, NOS; total prostatectomy, NOS
.7%
.8%
.3%
Prostatectomy WITH resection
Prostatectomy, NOS
Surgery, NOS
Unknown if surgery performed
.7% .4%
.5% .4%
81%
76%
34%
55%
37%
53%
Figure 2: Race of Prostate Cancer Patient Diagnosed in 2004
Florida vs. National
13%
Florida
Data from 7,627 patients
.1%
12%
1%
2%
73%
Florida
Data from 7,627 patients
National
Data from 117,366 patients
Source: NCDB, CoC, ACoS • Benchmark Reports, v8.0 - July 22, 2007
.2%
4%
14%
2%
77%
3%
National
Data from 117,366 patients
Source: NCDB, CoC, ACoS • Benchmark Reports, v8.0 - July 22, 2007
White
Black
Hispanic
Native American
Asian
Other/Unknown
11%
.1%
.1%
5%
4%
Florida
Data from 67 hospitals
51%
.3%
5%
Surgery only
Radiation only
Radiation & hormone therapy
Surgery & hormone therapy
2%
National
Data from 1,317 hospitals
Source: NCDB, CoC, ACoS • Benchmark Reports, v8.0 - July 22, 2007
Figure 5:
Hormone therapy only
Other specified therapy
No first course Rx
3% 3% 4%
3%
8% 4% 9%
6%
3% 4%
3%
5%
21%
Treatment Comparison
17%
SJH Florida National
Data from 1,373 patients Data from 7,627 patients Data from 117,366 patients
39%
17%
26% 23%
Source: SJH Cancer Registry Database • Retrieved on July 21, 2007
41%
Figure 3: Age of Prostate Cancer Patient Diagnosed in 2004
Florida vs. National
2,448
37
4 207
604
1,416
2911
Florida
Data from 7,627 patients
34,577
575
7
9,297
3,218
53
25,133
44,506
National
Data from 117,366 patients
Source: NCDB, CoC, ACoS • Benchmark Reports, v8.0 - July 22, 2007
16-29
30-39
40-49
50-59
60-69
70-79
80-89
90 and older
Table 3: Patient’s Age at Diagnosis – SJH
AGE 2000 2001 2002 2003 2004 2005 2006 TOTAL
Number Number Number Number Number Number Number Number
30-39 0 0 0 0 0 0 0 0
40-49 2 4 4 10 3 10 10 43
50-59 33 50 41 39 58 55 46 322
60-69 86 61 83 68 57 75 97 527
70-79 68 55 59 53 51 45 38 369
80-89 16 21 13 15 11 15 14 105
90-99 3 1 0 0 2 1 0 7
TOTAL 208 192 200 185 182 201 205 1,373
Source: SJH Cancer Registry Database • Retrieved on July 21, 2007
Figure 4a:
150
120
90
60
30
0
Surgery – SJH
None
Cryosurgery
143
Prostatectomy
Robotic Prostatectomy
116
All Others
121
97
81
67
58
50
51
55
47 43
39
38 36 36
38
26
31
26
30 23
19
13
13
16 19 18
6
9
0 0 0 0
4
2000 2001 2002 2003 2004 2005 2006
Source: SJH Cancer Registry Database
Retrieved on July 21, 2007
8

Figure 6a:
100
80
60
40
20
Figure 6c:
100
100
Figure 6b:
80
60
40
20
0
80
60
40
20
0
0
100 95 91 87 85 80
Stage I Stage II Stage III Stage IV Overall
364 cases 14,224 cases 1,429 cases 854 cases 16,871 cases
100 95 91 86 81 76
Five-year Observed Survival by Stage – SJH
(Diagnosed 1995-2001)
Five-year Observed Survival by Stage – Florida
(Diagnosed 1998-1999)
At diagnosis
1 year
2 years
3 years
75-84
Five-year Observed Survival by Stage – National
(Diagnosed 1998-1999)
At diagnosis
1 year
2 years
3 years
75-77
100 100 9896 99 97 100 100
92
97 94
89
93
85
90
86
90 87
80
83
65
57
49 45
84-86
10098 100 100 100 95 98 92 96 97 89 93 93 85
90 87
89 86
78
82
62
51 43 38
85-85.5
Stage I Stage II Stage III Stage IV Overall
9,748 cases 175,604 cases 23,430 cases 13,918 cases 222,700 cases
87-87.5
37-39
4 years
5 years
95% Confidence
Interval
Source: NCDB, Commission on Cancer, ACoS/ACS • Survival Reports, v3.0 – July 22, 2007
84-89
At diagnosis
1 year
2 years
3 years
4 years
5 years
100 100
95
100 99 100 100
92
97 94 9796 9692 8981 91 87 91 89 81
83
84 81 82
84 80
59
48
42
Stage I Stage II Stage III Stage IV Overall
Source: NCDB, Commission on Cancer, ACoS/ACS • Survival Reports, v3.0 – July 22, 2007
41-49
4 years
5 years
95% Confidence
Interval
Source: NCDB, Commission on Cancer, ACoS/ACS • Survival Reports, v3.0 – July 22, 2007
82-84
82
Hormone Therapy
Androgen Deprivation Therapy (ADT) is the mainstay of therapy for
advanced prostate cancer. ADT can be accomplished either medically or
surgically (orchiectomy) and the response and outcome are equivalent.
Medical castration is typically accomplished with a luteinizing hormonereleasing
hormone (LHRH) agonist. The target for ADT is a serum
testosterone level of

Cancer Registry Data Summary
2006 Statistics
In Florida, an estimated 98,960 cases were expected to be diagnosed in
2006, while 1,399,790 new cases were estimated nationally. According to
the 2006 Cancer Facts & Figures, cancer is the second most common cause
of death in the United States, which accounts for one of every four deaths.
During 2006, the Cancer Registry accessioned 2,045 new cases, 77% of
which were analytic cases that were diagnosed and/or treated at St. Joseph’s
Hospital, St. Joseph’s Women Hospital, Same Day Surgery, Radiation
Therapy Center, Outpatient Infusion Center and St. Joseph’s Children’s
Hospital of Tampa. The non-analytic cases account for 23% of patients that
were diagnosed and/or treated elsewhere (Table 6).
The gender distribution of St. Joseph’s Hospital analytic case population is
43% for males and 57% for females. American Cancer Society Facts &
Figures – 2006 estimated 51% male and 49% females diagnosed nationally
(Figure 9).
Race distribution continues to show similarities to previous years at 86%
white, 12% black and 2% other race (Figure 11). The two largest age
populations are 60-69 (25%) and 50-59 (21%), accounting for 46% of
the 2006 patient population. The third largest age group is 70- 79;
females accounts for 11% and males 10% (Figure 10).
Staging is essential in determining the choice of therapy and in assessing
prognosis. St. Joseph’s Hospital analytic cases by AJCC TNM staging
systems assess tumors in three ways: extent of the primary tumor (T),
absence or presence of regional lymph node involvement (N), and absence
or presence of distant metastases (M). These components determine a stage
of I, II, III, or IV; stage I being early stage and IV being advanced. Figure
12 shows slight similarities from 2006: Stage 0, (8%); Stage I, (21%); Stage
II, (24%); Stage III (13%); Stage IV, (14%); Unknown, (9%) and Stage Not
Applicable (N/A) (10%). This demonstrates that 54% of our patient
population was diagnosed with early stage disease (Stage II or less).
The top ten primary cancer sites (Figure 8) prevalence at St. Joseph’s
Hospital shows similarities to state and national comparison. Breast cancer
diagnoses at St. Joseph’s Hospital continue to remain in the forefront. This
is due to the comprehensive Breast Center at St. Joseph’s Women’s Hospital
and diagnosing more breast cases in Hillsborough County.
St. Joseph’s Hospital treatment modality (Figure 14) shows 38% of
patients had surgery alone, 6% received radiation therapy alone, 6%
received chemotherapy alone, while 34% had combined modality
treatment and 16% elected no treatment.
Figure 7 iIllustrating the five-year relative survival rates by SEER stage
comparison, shows favorable outcomes for St. Joseph’s Hospital top five
cancer sites.
Figure 7: Five-Year Relative Survival–SJH & U.S.; 1996-2002
100%
90
80
70
60
50
40
30
20
10
0
91 89
100 100
65 65
SJH
U.S.
19 16
61 63
Breast Prostate Colorectal Lung Non-Hodgkin’s
Lymphoma
Obtained from American Cancer Society 2007 Cancer Facts and Figures
Figure 8:
Top Ten Sites vs. State and U.S.
30%
25
26
SJH (Total–1,569)
FL (Total–98,960)
U.S. (Total–1,399,790)
26
25
24
20
18
17
15
10
14 15 13 13 13
13
11
10
8
5
0
444
5 4
3
3 3 3 3 3 3
5
4
1 1 1 1
Breast Lung Prostate Colorectal Non-Hodgkin’s Bladder Leukemia Corpus Uteri Melanoma Cervix All Others
Lymphoma
10

Table 6: Primary Site Tabulation for Cases in 2006
A total of 2,045 cases were diagnosed and/or treated at St. Joseph’s Hospital. The analytic cases of 1,569 accounted for 77% of the total population and the non-analytic cases of
476 accounted for 23%. American Cancer Fact & Figures–2006 estimated a total of 1,399,790 new cases were estimated for 2006 nationally, with 98,960 projected for Florida.
Primary Site Total Class Sex
A N/A M F
All Sites 2,045 1,569 476 930 1,115
Oral Cavity 37 26 11 26 11
Lip 0 0 0 0 0
Tongue 16 9 7 10 6
Oropharynx 2 1 1 2 0
Hypopharynx 0 0 0 0 0
Other 19 16 3 14 5
Digestive System 287 220 67 142 145
Esophagus 12 7 5 5 7
Stomach 20 17 3 11 9
Colon 122 85 37 50 72
Rectum 42 36 6 26 16
Anus/anal canal 11 9 2 5 6
Liver 22 18 4 18 4
Pancreas 40 32 8 20 20
Other 18 16 2 7 11
Respiratory System 287 225 62 172 115
Nasal/sinus 2 1 1 1 1
Larynx 23 12 11 20 3
Lung/bronchus 260 210 50 150 110
Other 2 2 0 1 1
Blood & Bone Marrow 111 76 35 55 56
Leukemia 72 52 20 35 37
Multiple Myeloma 26 21 5 14 12
Other 13 3 10 6 7
Bone 6 3 3 4 2
Connect/Soft Tissue 9 7 2 5 4
Skin 31 10 21 20 11
Melanoma 29 10 19 18 11
Other 2 0 2 2 0
Breast 478 405 73 7 471
Female Genital 148 114 34 0 148
Cervix Uteri 29 22 7 0 29
Corpus Uteri 61 48 13 0 61
Ovary 37 24 13 0 37
Vulva 15 14 1 0 15
Other 6 6 0 0 6
Male Genital 311 218 93 311 0
Prostate 297 205 92 297 0
Testis 14 13 1 14 0
Other 0 0 0 0 0
Urinary System 132 99 33 85 47
Bladder 75 54 21 57 18
Kidney/renal 51 41 10 24 27
Other 6 4 2 4 2
Brain & CNS 41 35 6 19 22
Brain (benign) 4 3 1 1 3
Brain (malignant) 25 21 4 12 13
Other 12 11 1 6 6
Endocrine 38 31 7 16 22
Thyroid 32 28 4 12 20
Other 6 3 3 4 2
Lymphatic System 106 82 24 54 52
Hodgkin’s Disease 19 14 5 8 11
Non-Hodgkin’s 87 68 19 46 41
Unknown Primary 15 13 2 10 5
Other/ill-defined 8 5 3 4 4
13 11

Figure 9:
2006 Gender Distribution
Compared to U.S.
Male
Female
Figure 11:
Race Distribution
2%
White
Black
Other
12%
51% 43%
49% 57%
86%
U.S.
SJH
Male cancer cases comprised 43% (679) of the total analytic cases and females comprised 57% (890).
The American Cancer Society Facts & Figures - 2005 estimates there will be 51% male and 49% females
diagnosed with cancer nationally.
Figure 10: Age by Gender Distribution Figure 12: AJCC Staging Distribution–1,569 total
(All Sites–Analytic Only)
220
200
180
160
140
120
100
80
60
40
20
0
12 16
10 10
6 8
17
46
51
147
0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
132
200
220
171
177
160
Male (679 Total)
Female (890 Total)
63
97
8
7
9%
(136)
13%
(200)
10%
(160)
14%
(224)
24%
(383)
8.4%
(131)
21.4%
(335)
Stage 0
Stage I
Stage II
Stage III
Stage IV
Unknown
N/A
Figure 13:
50%
40
Top Five Sites vs. State and U.S.
SJH
FL
U.S.
30
26
20
10
14 15
13 13 13
18 17
13
10 11
7
4
4 4
0
Breast Lung Prostate Colorectal Non-Hodgkin’s
Lymphoma
Figure 14:
Treatment Modality
Surgery
Surgery/Radiation Therapy
Chemotherapy
None
Surgery/Chemotherapy
Other Combined Therapy
22%
38%
9%
16%
9%
6%
12

Cancer Registry Report
The Cancer Registry is an integral part of St. Joseph’s Hospital Cancer
Institute. The primary function is to provide continuum data
management services under the leadership and support of the Cancer
Committee. Cancer data collection is available to the medical staff for
special studies, audits and research.
St. Joseph’s Hospital Cancer Registry initiated data collection in 1976
with over 40,000 accumulative cases. The registry reference year was
changed to 1990 for better control of maintaining current follow-up and
treatment on over 22,000 patients. Lifetime follow-up for former patients
is a vital component of our cancer program. Annual follow-up
encourages patients to continue their yearly medical supervision. The
goal is to maintain current follow-up on all patients in the Electronic
Registry System cancer database.
The registry utilizes the Electronic Registry System (ERS), which better
serves in data collection, analysis and quality improvement to meet the
Florida Cancer Data System (FCDS) and the National Cancer Database
call for data. The registry software has undergone extensive upgrades to
maximize the elements in providing quality data. The registry data is
used for a variety of screening, early detection and prevention programs.
The medical community can identify higher cancer incidents to increase
public awareness in both preventable and treatable diseases.
2006-2007 Cancer Registry Accomplishments
• Completed 2,045 abstracts for accession year 2006 by maintaining
over 90 percent abstract timeliness requirement
• Submitted 2006 data to National Cancer Database call for data to meet
Commission on Cancer Standards of both quality and timeliness
• Achieved an overall data accuracy of 95 percent per physician audit of
10 percent of analytic cases
• Maintained patient follow-up on over 10,000 eligible patients since
reference year 1990 with a success rate of over 90 percent
• Participated in state and nationwide cancer registry educational
activities annually
• Participated in National Cancer Database Study Cancer Program
Practice Profile Reports (CP3r) for colon and breast cancers
The Cancer Registry staff coordinates Cancer Conferences for case
presentations. Conferences are held weekly on Fridays (7:30-8:30am) in
the St. Joseph’s Hospital Medical Arts Building. Breast conferences are
held every other Tuesday (noon) at St. Joseph’s Women’s Hospital
Pavilion 4th floor classrooms. These forums are used to provide
treatment options and improvements in patient care throughout the
Tampa Bay area. Please contact the Cancer Registry at (813) 870-4987 to
schedule case presentations.
St. Joseph’s Hospital Cancer Committee encourages the use of Registry
data. The Cancer Registry receives numerous requests for statistical
reports. Data is utilized for the following: study analysis, annual statistics,
reports to the State Cancer Registry and the National Cancer Data Base,
research activities, survival analysis, quality management studies,
community education, health care planning/delivery and outcome
evaluation/improvement.
The Cancer Registry would like to thank our volunteers, physicians and
staff for the collaborative efforts in providing the most current follow-up
and treatment information, to assure the most achievable outcomes of
accurate data in the registry.
Victoria Young, MBA, CTR
Cancer Registry Coordinator
Cancer Liaison Physician Report
St. Joseph’s Hospital
The community cancer program at St. Joseph’s Hospital is approved by
the American College of Surgeons Commission on Cancer. As the Cancer
Liaison Physician at St. Joseph’s Hospital, I am committed to our cancer
program, supporting compliance and maintenance of Commission on
Cancer standards, facilitating a working relationship with the American
Cancer Society and working closely with our cancer committee to
improve the quality of our cancer care.
This past year, we worked more closely with the American Cancer
Society having John Surprenant, Director of the Cancer Institute, serving
on their Cancer Control Committee and an American Cancer Society
representative serving on our Cancer Committee. St. Joseph’s Hospital was
recently recognized by the American Cancer Society for our newly organized
and expanded Reach to Recovery Program.
We are currently participating in a Commission on Cancer study on the
“Impact of Neoadjuvant Therapy on Staging for Rectal and Breast Cancer
Cases.” The results of this study will be used to identify ways to improve
our treatment of these cancers.
Dr. James Christensen, Dr. Chris George and I preside at our weekly
multidisciplinary cancer conferences. They are well attended and many
prospective cases are presented, which positively impact the treatment
of our patients.
I serve as an active member and chairman of our Cancer Committee,
working closely with John Surprenant, Director of the Cancer Institute,
and Victoria Young, Cancer Registrar, to promote our Cancer Institute and
physicians, to improve cancer care, to publish the annual report and to
participate in the periodic American College of Surgeons Commission on
Cancer survey for re-accreditation.
Thank you for the honor and privilege of serving as St. Joseph’s Hospital
Cancer Liaison Physician.
Anthony N. Brannan, M.D.
Cancer Liaison Physician
13

Cancer-Related Programs and Services
14
da Vinci ® Surgical System
The da Vinci Surgical System is highly sophisticated, minimally invasive
technology that translates each motion of a surgeon’s hands into precise
movements of the micro-instruments for a more accurate surgical
procedure. The size, precision and flexibility of instruments make the
surgical system ideal for prostatectomy where the cancer tissue is tightly
confined and closely surrounded by nerves. It is available at St. Joseph’s
Hospital and is operated by our experienced team of physicians.
Diagnostic and Interventional Radiology Services
St. Joseph’s Hospital provides a full array of advanced diagnostic and
interventional imaging services and procedures. In recent years, diagnostic
radiology has made giant strides in the development of minimally invasive
devices and techniques that can better detect cancer.
St. Joseph’s Hospital radiology physicians and staff are leaders in their fields
and have access to the most advanced technology available today. The
program is ACR accredited. The department is staffed by board-certified and
fellowship-trained radiologists in areas of neurointerventional, interventional,
pediatric, nuclear medicine, MRI, musculoskelatal and breast imaging
specialties. The radiology team is supported by ARRT-certified technologists in
all specialty modalities.
Services provided by the department include breast MRI, breast ultrasound,
full-field digital mammography, PET/CT, stereotactic core needle breast biopsy,
CT, ultrasound and MRI-guided biopsy services, nuclear medicine services
including sentinel lymph node mapping/lymphoscintigraphy, as well as
routine fluoroscopy, MRI, CT and ultrasound.
Interventional imaging includes minimally invasive procedures including
chemo-embolization for treating liver and bone metastatic disease, RF and
cryoablation procedures, aneurysm coilings, stenting and central-line
placements. All modalities are supported by a state-of-the-art 3D post
processing service that provides surgical mapping, stroke analysis and
planning for patient treatments. The radiology department utilizes all digital
imaging equipment and includes 64- and 128-slice CT scanners capable of
cardiac imaging, DR radiology rooms and a comprehensive digital PACS
system for image analysis.
Fred J. Woods Radiation Therapy Center
The Fred J. Woods Radiation Therapy Center is a state-of-the-art facility,
which has been part of St. Joseph’s Hospital since 1969. It is staffed with
board-certified radiation oncologists, physicists and dosimitrists. The
Center has ten certified radiation technologists, as well as two oncology
trained nurses to provide skilled, compassionate care to the cancer patient.
Existing technology includes: two Varian Clinac 23 EX linear accelerators
with Intensity Modulated Radiation Therapy (IMRT) capabilities; a
dedicated advanced light speed GE CT scanner; Stereotactic Radiosurgery
(SRS); Nucletron High Dose Rate Brachytherapy (HDR); Superficial; and
the Phillips Pinnacle Treatment Planning System with fusion capabilities
to receive diagnostic MRI, PET and CT scan.
The Center provides a full-range of treatment options, including
mammosite, prostate seed implants and use of sir spheres for colon and
liver metastasis in addition to traditional external beam therapy. The
Center is approved to participate in Radiation Therapy Oncology Group
clinical trials through the American College of Radiology.
Outpatient Infusion Center
The Outpatient Infusion Center offers convenience for patients who require
infusion of medications, including those with central lines. The staff works
primarily with cancer patients undergoing chemotherapy and those with
blood disorders.
Services and treatments provided include infusion of chemotherapy
agents, biological response modifiers, central line catheter care,
hydration, immunomodulators, IV anti-emetics therapy, IV immune
globulin, monoclonal antibodies, subcutaneous injections, therapeutic
phlebotomy and transfusion of blood products.
Pathology Services
The Pathology Department at St. Joseph Hospital offers state-of-the-art
diagnostic services in cytology, anatomical, clinical and surgical pathology
and is supported by a variety of specialty laboratories including: histology,
immuno histochemistry, electron microscopy, flow cytometry and molecular
diagnostics. The department is staffed by 11 board-certified pathologists
who are experts in their subspecialty areas.
St. Joseph’s Children’s Hospital Hematology/Oncology Center
St. Joseph’s Children’s Hospital Hematology/Oncology Center is a
comprehensive program that incorporates the latest inpatient and outpatient
treatments for all forms of childhood cancers. We are a member of the
Children’s Oncology Group (COG), an international research cooperative that
designs and reviews the most advanced treatments for childhood cancer. We
are also a member of the Florida Association of Pediatric Tumor Programs.
Our participation in COG provides for affiliation in CureSearch, which
unites the world’s largest cancer research organizations (COG and National
Childhood Cancer Foundation) in a shared mission to cure childhood
cancer through research. Dr. Cameron Tebbi, a nationally known expert in
pediatric oncology, leads a team of board-certified pediatric oncologists,
practitioners and research nurses as part of our center. There are currently
78 COG studies open to enrollment with 30 active patients. Additionally,
there are two pharmaceutical studies available to qualified participants.
St. Joseph’s Children’s Hospital Hematology/Oncology Center provides a
seven-bed state-of-the-art infusion center, as well as dedicated 15-bed
inpatient unit in the Cancer Institute. Greater than 60 percent of our
nursing staff has attained CPN or CPON certification. The remainder of
the team is comprised of certified child life specialists, pediatric social
workers, chaplains, audiologists, occupational, physical and speech
therapists, pediatric radiation oncologists and a clinical psychologist.
The Breast Center at St. Joseph’s Women’s Hospital
The Breast Center at St. Joseph’s Woman’s Hospital provides care,
guidance, information, screening, diagnosis and treatment for breast
cancer patients. The Center offers the highest level of expertise,
compassion and respect in a convenient and comfortable setting.
The Breast Center has dedicated board-certified physicians who are
specialists in their respective fields, and is further enhanced with a dedicated
nurse navigator. The nurse navigator is an experienced specialist who
coordinates the details of patient care, provides personalized information
and support, assists with appointments and scheduling, and is the patients’
link to physicians, resources and therapies.
The Breast Center’s state-of-the-art diagnostic imaging technology includes:
• Digital mammography (breast x-ray)
• Stereotactic biopsy – minimally invasive, state-of-the-art technology
that causes less stress and pain to the patient
• Needle localization and biopsy – a specialized mammography
technique that pinpoints the location of the breast lesion
• Breast ultrasound – the use of sound waves to differentiate solid tumors from cysts
• Breast MRI

Cancer Patient Support Services
Cancer HelpLine/Cancer Outreach
St. Joseph’s Hospital Cancer Institute has a no-cost, confidential information
line staffed by a nationally certified oncology nurse. Callers receive cancer
information and referrals to physicians and community services such as free
and low-cost cancer screenings. Call (813) 870-4123.
Enterostomal Therapy Clinic
St. Joseph’s Hospital offers an Outpatient Enterostomal Therapy (ET)
Clinic for new ostomy patients and any patient who experiences problems
related to their ostomy. Patients must call their primary physician to
request a referral. Call (813) 870-4418 to schedule an appointment.
Hispanic Breast Cancer Support Group
This free monthly group is designed for Spanish-speaking women with
breast cancer, survivors and their family members. Call (813) 870-4747.
Look Good...Feel Better
This program is available for women before, during and after treatment.
Receive a consultation at no charge with a beauty specialist who provides
cosmetic advice, hair/wig styling tips and free makeup kits. Call the
American Cancer Society at (800) 227-9954.
Lymphedema Program
Housed at St. Joseph’s Hospital, this program combines manual lymph
drainage with compressive bandaging, personalized exercise programs
and skin care to help patients manage symptoms and reduce swelling
and pain. Call (813) 870-4877, ext. 1, for more information.
Nutrition
Nutritional counselors are available to assist patients with specific
dietary needs. Call (813) 870-4420.
Outpatient Counseling Services:
BayCare Life Management
Outpatient counseling is a voluntary treatment choice for those needing
short- or long-term behavioral health care. Counseling is done in one of
BayCare Life Management’s convenient locations throughout the Tampa
Bay area. Treatment is accomplished in individual, family and smallgroup
formats. For further information, call (813) 936-0474, ext. 3.
OVACOME
Ovarian and gynecological cancer support group meets on the third
Tuesday of every month from 6-8pm in the Medical Arts Building
Auditorium. Free support group for patients and significant others. Call
the Contact Center at (813) 870-4747 or Ovacome at (813) 223-9108
for more information, or visit www.ovacome.us.
Pain Management Specialist
St. Joseph’s Hospital Pain Management Specialists are available for all
patients. Physician referral is required.
Palliative Care
St. Joseph’s Hospital offers a very specialized team that works with your
attending physician to assist in relieving physical pain and suffering,
while also providing emotional and family counseling. Our goal is to
help you and your family make the most of life. Call (813) 870-4114.
Pastoral Care
Our Pastoral Care Department provides supportive spiritual care to
cancer patients and their families, including psycho-spiritual counseling,
prayer, religious services, meditation and referrals. Call (813) 870-4258
or (813) 872-3950.
Prostate Cancer Support Group: Man-to-Man
A free American Cancer Society support program for prostate cancer
survivors and their significant others. Meets monthly. Guest speakers
and topics vary each month. Contact the American Cancer Society at
1 (800) 227-9954 or our Cancer HelpLine at (813) 870-4123 for more
information.
Pulmonary Rehabilitation
Provides information and support for those with respiratory illness and
breathing difficulties. Call (813) 870-4844, ext. 4.
Social Services
Social workers are available to help plan for hospital discharge,
including referrals to home health, skilled nursing or rehabilitation
services. Call (813) 870-4974 or (813) 872-3915.
Tampa Area Ostomy Support Group
The Tampa Area Ostomy Support Group is sponsored by St. Joseph’s
Hospital and is supported by four local WOCN nurses. All ostomates
and their support persons are invited to attend. Meetings are held every
other month on the third Saturday except when otherwise notified.
There is no fee or registration required. Contact one of the following
nurses for more information: Pam Brown, (813) 870-4785;
Beverly Higbea, (813) 870-4418; Barbara Bagby, (813) 558-4900, or
Nancy Scott, (813) 972-8438.
15

2006-2007 Cancer Program Highlights
Cancer Committee Goals
• Increase patient and family satisfaction with the palliative care program.
Achieved.
• Increase physician, nursing and ancillary staff cultural awareness and
sensitivity in our diverse patient populations. Achieved.
• Develop in conjunction with Greater Tampa Unit of the American Cancer
Society a Patient Resource Center. In process—on target.
• Enhance resources on hospital cancer Web site. Achieved.
• Assure that Stage I-III breast cancer patients receiving highly emetogenic
chemotherapy receive potent antiemetic therapy (5 HT Blockage). Achieved.
• Assure that colorectal cancer patients with Stage II-III disease receiving
chemotherapy have recorded the body surface area and planned dose
documented in the medical record. Achieved.
• Develop process to evaluate appropriate drug use for new drugs which
are not yet funded by Medicare. Achieved.
• Develop tool for medical oncologists to order outpatient therapies in a
consistent manner. Achieved.
• Develop and maintain “wish list” of opportunities for potential donors for
St. Joseph’s Hospitals Foundation. Achieved.
• Enhance drug replacement program for safety net cancer patients in the
Outpatient Infusion Center. Achieved.
Screenings
1,224 participants/66 abnormals identified
• African-American Men’s Health Forum
• Colorectal Awareness and Screening Campaign
• St. Joseph’s Hospital Prostate Screening (2)
Support Groups
54 support groups were held with 799 people in attendance.
• Hispanic Breast Cancer
• Man-to-Man
• Ostomy Support
Community Educational Seminars
• Look Good...Feel Better
• Mindfulness Meditation
• Ovacome
• Colon Cancers, Hemorrhoids and Fissures – Dr. Lori Slezak
• Continuing Education Conferences for Medical Staff
• Genetic Screening in Cancer – Rebecca Stuphen, M.D.
• Gynecological Cancers – Dr. Giselle Ghurani
• Healing Touch Training Seminar
• Molecular Diagnostics – Genotypes Predicts Risk of Toxicity to
Irinotecan – Maura Pieritti, Ph.D.
• Prostate Cancer and Robotics Conference – Dr. Frank Mastandrea
• Targeted Therapies for Cancer – Dr. Alex Mirakian, Dr. Alison Calkins
and Dr. Gabriel Gonzales-Portillo
Sponsorships
• African-American Men’s Health Forum
• American Cancer Society’s Cattlebaron’s Ball
• American Cancer Society’s Reach to Recovery Luncheon and Fashion Show
• Ovacome Celebrate Hope
• St. Joseph’s Hospital Golf Classic
• Susan G. Komen Race for the Cure
• Tancredi Colon Cancer Prevention Awareness Run
Special Events
• Cancer Survivors’ Day Celebration – June 5
• Lilly Art Exhibit: A Woman’s Journey through Cancer – month of October
• Oncology Nurses’ Week
• National Registrar’s Week
• American Cancer Society’s Daffodil Days
• Hired Nurse Navigator for The Breast Center – Susan Baker, R.N., Ph.D.
candidate
• Purchased High Dose Rate Brachytherapy Technology and began use –
May 8
• Jointly sponsored Oncology Nursing Society review course with
Morton Plant Mease
• Chris Hubbard, American Cancer Society Patient Services
Representative, gave presentation at Tumor Conference on range of
services available through the American Cancer Society
• Initiated Safety Net Drug Replacement Program in Outpatient Infusion Center
• Dr. Anthony Brannan and John Surprenant were guest speakers at the
Florida Council of Aging Conference on August 16. Spoke on
Colorectal Cancer Awareness and Screening.
• Donated 26 wigs to patients
• Reach to Recovery Program
• Innovative program using hospital breast cancer survivors to visit new
breast cancer patients was started on April 14, 2006. Trained 19
volunteers and saw 97 patients in 2006.
• Purchased new technology to support Cancer Conferences at St. Joseph’s
Women’s Hospital
• Florida Dialogue on Cancer
• Participation in Quality Improvement projects through Six Sigma
– CI-3 patient satisfaction with pain management
– Sitter usage
– Fall prevention
– Increasing effective communication at time of handoff to radiology
– Outpatient Infusion – Maximizing chemotherapy drug reimbursement
– New Drug Decision Matrix Process workout
16

Philanthropy (Fund-Raising Events)
• Carrabba’s Children’s Golf Classic
• Hope on Wheels – Krewe event to support cancer research
• Order of the Eastern Star – To support cancer research
• Bras for a Cause – In support of activities at The Breast Center
Grants
• Joy McGann Community Enrichment Foundation – (Service) To support
bilingual breast cancer patients with access to mammograms and biopsies
• Amgen – (Educational) To support Oncology Nursing Society Review Course
• Komen – The Breast Center and Cancer Outreach Nurse
2006-2007 Seminars
2006
• African-American Men’s Health Forum Event
• African-American Men’s Prostate Screening
• Cervical Cancer and Human Papillomavirus
• Ladies Night Out – Breast Cancer: Are You At Risk
• Ladies Night Out – Mid-Life Woman: Colon Cancer, Hemorrhoids
and Fissures
• Ladies Night Out – Ovarian Cancer and Other Gynecological Cancers
• Prostate Cancer Screening
2007
• Advanced Prostate Surgery Using Robotic Technology
• Ladies Health Fair – Screening Mammogram
• Ladies Night Out – Breast Cancer: Are You At Risk
• Ladies Night Out – Breast Health
• Ladies Night Out – Ovarian Cancer and Other Gynecological Cancers
• Lymphedema Educational Conference
• Men’s Night Out
• Palliative Care: LIVING with Advanced Illness
• Prostate Cancer Screening
• Radical Robotic Prostatectomy
• Together Facing Lung Cancer
• Urological Issues
Marketing and Public Relations
• 2006 and 2007 Colorectal Cancer Awareness Campaign – collaborative
partnership with CVS Pharmacies and WFTS - ABC 28
– More than 95,000 test kits given out
– Created hotline for questions staffed by registered nurse
– Live call-in shows with physicians, nurses and pharmacists available
to answer consumer’s questions
– Media stories about the importance of colorectal cancer screening,
guidelines for screening and patient stories
Strategic Planning
American Cancer Society Partnership
• John Surprenant on Unit Board
• John Surprenant to chair Cancer Control
• Formal Partnership Agreement signed
• Advocacy efforts supported
• Participated in research awards dinner
• Participated in Florida Division – Volunteers launch event
• Participated in African-American Women’s Cancer Summit in Orlando
• Participated in launch of LifeLine Program for area
• Participate in educational session on Hope Lodge
Moffitt Affiliation
Our affiliation with the H. Lee Moffitt Cancer Center & Research
Institute further expands our services so that patients are receiving the
most up-to-date, advanced cancer care available as well as access to
nationally recognized clinical trials. The affiliation reinforces the concept
of delivering primary cancer care in our highly regarded hospital while
tapping the expertise and resources of academic researchers to assist in
the treatment of rare and complicated cancers.
New Medical Staff Oriented
• 24 new physicians on staff and one ARNP
Cancer Research
St. Joseph’s Hospital Cancer Institute is an affiliate member of the NCI-designated H. Lee Moffitt Cancer Center & Research Institute. Through this
affiliation, St. Joseph’s Hospital physicians can take part in device trials, phase II & III Cooperative Group trials such as the Radiation Therapy Oncology
Group, as well as selected phase II Moffitt Institutional trials. The Cancer Institute at St. Joseph’s Hospital also develops and initiates clinical trials.
Recently, the Cancer Institute Department of Radiation Therapy received FDA approval as the only site in the nation to study brachytherapy to the liver
in patients with metastatic breast cancer. In addition, the pediatric cancer program at St. Joseph’s Children’s Hospital of Tampa takes part in NCI national
clinical trials, as will as pediatric laboratory research.
17

Cancer Program Leaders
Anthony N. Brannan, M.D.
Cancer Committee Chair
ACoS Physician Liaison
James Christensen, M.D.
Breast Cancer Conference Coordinator
Christopher George, M.D.
Medical Director
Chief of Oncology
Cancer Conference Coordinator
John L. Surprenant, MA, MDIV, MPH
Administrative Director
Important Phone Numbers
Breast Center: (813) 872-2973
Cancer Helpline/Outreach: (813) 870-4123
Cancer Institute–Administration: (813) 870-4991
Cancer Institute–Inpatient Unit (CI-3): (813) 870-4588
Cancer Registry: (813) 870-4987 (phone)
(813) 870-4209 (fax)
Cancer Research/Clinical Trials: (813) 870-4257
Diagnostic Center Scheduling: (813) 870-4826
Pediatric Hematology/Oncology: (813) 870-4824
Outpatient Chemotherapy/Infusion: (813) 870-4246
Palliative Care Services: (813) 870-4114
Radiation Therapy: (813) 870-4160
Radiology Scheduling: (813) 870-4601
Surgery Scheduling: (813) 870-4441
18

Index of Physicians Associated
with Cancer Program
by last name and specialty
Definition of Terms
American College of Surgeons
Commission on Cancer (ACoS CoC)
The organization that surveys
and approves cancer programs.
Analytic (A)
Pertains to those cases initially
diagnosed and/or receiving
their first course of treatment
at St. Joseph’s Children’s Hospital
of Tampa, St. Joseph’s Hospital,
and St. Joseph’s Women’s Hospital.
Non-analytic (NA)
A case diagnosed and treated
elsewhere prior to being seen at
St. Joseph’s Children’s Hospital of
Tampa, St. Joseph’s Hospital, and
St. Joseph’s Women’s Hospital.
Cases that were treated more than
four months after initial diagnosis.
Cases that were initially diagnosed
at autopsy are considered nonanalytic
as well.
Florida Cancer Data System
The FCDS is an incidence registry
for the State of Florida. FCDS is a
cancer registry administered by the
Florida Department of Health and
is operated and maintained by the
Sylvester Comprehensive Cancer
Center at the University
of Miami School of Medicine.
AJCC Stage System
The registry records stage using the
AJCC (American Joint Committee
on Cancer) Manual for staging
guide. Stage 0, I, II, III, IV
or Unknown.
SEER
National Cancer Institute
Surveillance, Epidemiology,
and End Results
NCDB
National Cancer Data Base
Relative Survival
The ratio of observed survival
rate to the expected rate for a group
of people in the general population
similar to the patient group with
respect to race, sex and age.
If any physician has been omitted, please contact Julieann Ramsey at (813) 870-4991.
To be revised May 2008.
Observed Survival Rate
Rates computed by the actuarial
method, compounding survival in
one-month intervals from the date
of diagnosis, with death from
any cause as the endpoint.
Accuracy of the Registry data
contained in the 2006 Annual
Report depends upon complete
documentation in the medical
record. If the treatment plan
is not known upon discharge of
the patient, the Cancer Registry
contacts the appropriate physician’s
office to ascertain if the first course
of treatment was given at another
institution. In some cases, patients
initially refuse treatment or
subsequently receive treatment
after the first four months.
Cancer Registry Staff
Victoria Young, MBA, CTR
Cancer Registry Coordinator
Laquita Malone
Cancer Data Technician
Vacant
Cancer Registrar
19

Advanced medicine in the right hands. SM
3001 W. Dr. Martin Luther King Jr. Blvd.
Tampa, FL 33607
www.stjosephstampa.com
(813) 870-4991
St. Joseph’s Hospitals Foundation relies on the generous support of our community to continually improve patient care at St. Joseph’s
Hospital, St. Joseph’s Women’s Hospital and St. Joseph’s Children’s Hospital of Tampa. Funds contributed make possible new facilities
and equipment, community education and outreach, and special programs to sustain excellence. Individuals, businesses and
foundations provide funding through an array of programs, campaigns and events. For more information on how you can help, call
(813) 872-0979 or visit www.stjosephshospital-foundation.org.
sjb080418-0708